Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?

  • Marie VoglimacciEmail author
  • Erwan Gabiache
  • Amélie Lusque
  • Gwenaël Ferron
  • Anne Ducassou
  • Denis Querleu
  • Stéphanie Motton
  • Elodie Chantalat
  • Frédéric Courbon
  • Alejandra Martinez
Original Article



Aim of the study was to assess impact of pretherapeutic FDG-PET/CT metabolic parameters on response to chemoradiotherapy (CRT) and survival in locally advanced cervical cancer (LACC) patients without paraaortic lymph node involvement.


LACC patients treated with CRT without macrometastatic involvement after paraaortic surgical staging were included. All patients had received at least 45 Gy radiotherapy and five cycles of platinum-based chemotherapy. High-risk histologies were excluded. Two senior nuclear physician experts in gynaecologic oncology reviewed all PET/CT exams, and extracted tumor SUVmax, MTV, and TLG (standardized uptake value, metabolic tumor volume, and total lesion glycolysis respectively). Response to CRT was assessed with a pelvic MRI done after 45 Gy. Medical charts were reviewed for clinical, pathology, and survival data.


Ninety-three patients were included in the study. The overall survival (OS) rates at 2 and 5 years were 83.0% [95%CI: 72.5–89.8] and 71.2% [57.5–81.2] respectively. The RFS rates at 2 and 5 years were 72.5% [61.5–80.9] and 64.4% [52.3–74.2] respectively. Higher cervical SUVmax and TLG were significantly associated with poor response to CRT. In multivariate analysis, cervical SUVmax was the main predictive factor for OS.


Cervical tumor SUVmax was demonstrated to be a non-invasive prognostic biomarker for response to treatment and survival in LACC patients without paraaortic involvement. SUVmax and other PET/CT metabolic parameters require further prospective investigation to help tailoring of local treatment.


Cervix cancer SUV Prognosis Chemoradiotherapy FDG-PET/CT 


Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors of this article have no relevant relationships that could be perceived as a real or apparent conflict of interest.


  1. 1.
    Global Cancer Observatory, OMS. Estimated number of incident cases, worldwide (top 10 cancer sites) in 2012. Disponible sur
  2. 2.
    Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S43–S103. Scholar
  3. 3.
    Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72–83. Scholar
  4. 4.
    Chuang LT, Temin S, Camacho R, et al. Management and care of women with invasive cervical cancer : American Society of Clinical Oncology resource-stratified clinical practice guideline. J Glob Oncol. 2016;2(5):1–30. Scholar
  5. 5.
    Gouy S, Morice P, Narducci F, et al. Nodal-staging surgery for locally advanced cervical cancer in the era of PET. Lancet Oncol. 2012;13(5):e212–20. Scholar
  6. 6.
    Sagae S, Monk B, Pujade-Lauraine E, Gaffney D. Advances and concepts in cervical cancer trials: a roadmap for the future. Int J Gynecol Cancer. 2016;26:199–207. Scholar
  7. 7.
    Hasenburg A, Salama JK, Van TJ, Amosson C, Chiu JK, Kieback DG. Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer. Gynecol Oncol. 2002;326:321–6. Scholar
  8. 8.
    Chantalat E, Vidal F, Leguevaque P, et al. Para-aortic workup in locally advanced cervical cancer: heterogeneity is still the rule. Results from a retrospective multicenter study. Arch Gynecol Obstet. 2015;293(5):1081–6. Scholar
  9. 9.
    Sapienza LG, Gomes MJL, Calsavara VF, Leitao MM Jr, Baiocchi G. Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer ? A systematic review and meta-analysis of randomized clinical trials. Gynecol Oncol. 2017;144(2):312–317.
  10. 10.
    Oh D, Lee JE, Huh J, Park W, Nam H, Choi Y. Prognostic significance of tumor response as assessed by sequential 18 F-Fluorodeoxyglucose-positron emission tomography / computed tomography during concurrent chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2013;87(3):549–54. Scholar
  11. 11.
    Selman TJ, Mann C, Zamora J, Appleyard T-L, Khan K. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta- analysis. Can Med Assoc J. 2008;178:855–62.CrossRefGoogle Scholar
  12. 12.
    Margulies AL, Peres A, Barranger E, et al. Selection of patients with advanced-stage cervical cancer for para-aortic lymphadenectomy in the era of PET/CT. Anticancer Res. 2013;33(1):283–6.PubMedGoogle Scholar
  13. 13.
    Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res. 2008;14(16):5236–41. Scholar
  14. 14.
    Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110(8):1738–44. Scholar
  15. 15.
    Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer. 2009;116(6):1469–75. Scholar
  16. 16.
    Leseur J, Roman-Jimenez G, Devillers A, et al. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer. Radiother Oncol. 2016;120(3):512–8. Scholar
  17. 17.
    Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M. [18F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol. 2016;11:43. Scholar
  18. 18.
    Roman-Jimenez G, Ospina JD, Leseur J, et al. Investigating the contribution of pre- and per-treatment 18F-FDG PET-CT segmentation methodologies for post-treatment tumor recurrence prediction in cervical cancer. IRBM. 2013;34(4-5):274–7. Scholar
  19. 19.
    Boellaard R, Delgado-Bolton R, WJG O, et al. FDG PET / CT : FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
  20. 20.
    Kidd EA, El I, Siegel BA, Dehdashti F, Grigsby PW. Gynecologic oncology FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol. 2012;127(1):136–40. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Chung HH, Cheon GJ, Kim JW, Park NH, Song YS. Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix. Eur J Nucl Med Mol Imaging. 2017;44(11):1862–1869. Scholar
  22. 22.
    Sarker A, Im H-J, Cheon GJ, Chung HH, Kang KW, Chung J-K, et al. Prognostic implications of the SUVmax of primary tumors and metastatic lymph node measured by 18F-FDG PET in patients with uterine cervical cancer. A meta-analysis. Clin Nucl Med. 2016;41(1):34–40. Scholar
  23. 23.
    Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S, Hiramatsu Y. The predictive value of measurement of SUVmax and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix. Gynecol Oncol. 2010;119(1):81–6. Scholar
  24. 24.
    Kidd EA, Spencer CR, Huettner PC, et al. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer. 2009;115(15):3548–54. Scholar
  25. 25.
    Wang JZ. Sequential magnetic resonance imaging of cervical cancer: the predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy. Cancer. 2010;116(21):5093–101. Scholar
  26. 26.
    Taïeb S, Faivre-Pierret M, Nickers P, Lesoin A, Narducci F, Ceugnart L. IRMfonctionnelle : nouvel outil pour prédire la réponse des cancers du col utérin à la chimioradiothérapie concomitante ? Imag la Femme. 2011;21(4):143–7. Scholar
  27. 27.
    Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer. Hell J Nucl Med. 2016;19(3):254–68. Scholar
  28. 28.
    Schwarz JK, Ph D, Siegel BA, Dehdashti F, Grigsby PW, Louis S. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2011;83(1):185–90. CrossRefPubMedGoogle Scholar
  29. 29.
    Scarsbrook A, Vaidyanathan S, Chowdhury F, Swift S, Cooper R, Patel C. Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017;44:581–8. Scholar
  30. 30.
    Kidd EA, Thomas M, Siegel BA, Dehdashti F, Grigsby PW. Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys. 2012.
  31. 31.
    Ueno Y, Lisbona R, Tamada T, Alaref A, Sugimura K, Reinhold C. Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer. Br J Radiol. 2017;90(1075):20170035.CrossRefGoogle Scholar
  32. 32.
    Yoo J, Choi JY, Moon SH, Bae DS, Kim B. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using F-Fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer. 2012;22(7):1226–33. Scholar
  33. 33.
    Chong GO, Jeong SY, Park S, Lee YH, Lee S. Comparison of the prognostic value of F-18 pet metabolic parameters of primary tumors and regional lymph nodes in patients with locally advanced cervical cancer who are treated with concurrent chemoradiotherapy. PLoS One. 2015:10(9):e0137743. Scholar
  34. 34.
    Crivellaro C, Signorelli M, Guerra L, et al. 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecol Oncol. 2012;127(1):131–5. Scholar
  35. 35.
    Burger IA, Vargas HA, Donati OF, et al. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecol Oncol. 2013;129(3):586–92. Scholar
  36. 36.
    Akkas BE, Demirel BB, Dizman A, Vural GU. Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer? Ann Nucl Med. 2013;27(8):756–63. Scholar
  37. 37.
    Maharjan S, Sharma P, Patel CD, et al. Prospective evaluation of qualitative and quantitative 18F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix. Nucl Med Commun. 2013;34(8):741–8. Scholar
  38. 38.
    Onal C, Reyhan M, Parlak C, Guler OC, Oymak E. Prognostic value of pretreatment F-18-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy. Int J Gynecol Cancer. 2013;23(6):1104–10. Scholar
  39. 39.
    Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol. 2006;101:147–51. Scholar
  40. 40.
    Im H, Yoon H, Seong E, et al. Prognostic implication of retrocrural lymph node involvement revealed by 18 F-FDG PET / CT in patients with uterine cervical cancer. Nucl Med Commun. 2014;35(3):268. Scholar
  41. 41.
    Pan L, Cheng J, Zhou M. The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol. 2012;138(2):239–46.
  42. 42.
    Cima S, Perrone AM, Castellucci P, et al. Prognostic impact of pretreatment fluorodeoxyglucose positron emission tomography/computed tomography SUVmax in patients with locally advanced cervical cancer. Int J Gynecol Cancer. 2018;28(3):575–580. CrossRefPubMedGoogle Scholar
  43. 43.
    Huang SC. Anatomy of SUV. Nucl Med Biol. 2000;27(7):643–6. Scholar
  44. 44.
    Lodge MA. Repeatability of SUV in oncologic 18F-FDG PET. J Nucl Med. 2017;58(4):523–532. Scholar
  45. 45.
    Lucia F, Visvikis D, Desseroit M, et al. Prediction of outcome using pretreatment 18 F-FDG PET / CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017;45(5):768–786. Scholar
  46. 46.
    Henriksson EVA, Kjellen E, Wahlberg P, Ohlsson T, Wennerberg J, Brun EVA. 2-Deoxy-2- [ 18 F ] Fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. Anticancer Res. 2007;2160:2155–9.Google Scholar
  47. 47.
    Yu H, Caldwell C, Mah K, Mozeg D. Coregistered FDG PET / CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging. 2009;28(3):374–83.CrossRefGoogle Scholar
  48. 48.
    Eary JF, Sullivan FO, Sullivan JO, Conrad EU. Spatial heterogeneity in sarcoma 18 F-FDG uptake as a predictor of patient outcome. J Nucl Med. 2008;49(12):1973–9. Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Marie Voglimacci
    • 1
    Email author
  • Erwan Gabiache
    • 2
  • Amélie Lusque
    • 3
  • Gwenaël Ferron
    • 1
  • Anne Ducassou
    • 4
  • Denis Querleu
    • 5
  • Stéphanie Motton
    • 1
  • Elodie Chantalat
    • 1
  • Frédéric Courbon
    • 2
  • Alejandra Martinez
    • 1
  1. 1.Department of Surgical OncologyIUCT-OncopoleToulouse Cedex 9France
  2. 2.Department of Nuclear MedicineIUCT-OncopoleToulouseFrance
  3. 3.Department of BiostatisticsIUCT-OncopoleToulouseFrance
  4. 4.Department of RadiotherapyIUCT-OncopoleToulouseFrance
  5. 5.Department of Surgical OncologyInstitut BergoniéBordeauxFrance

Personalised recommendations